Gorgulu Gokşen, Kole Merve Çakir, Ayaz Duygu, Kuru Oguzhan, Gokcu Mehmet, Sanci Muzaffer
Ann Ital Chir. 2022;93:562-565.
Aggressive angiomyxoma is a type of mesenchymal tumor occurring predominantly in the pelvic and perineal region. The aim of our study was to reveal our experience with gonadotropin-releasing hormone (GnRH) treatment in patients with angiomyxoma and provide a comprehensive review of management.
This study is a case-series including seven female patients diagnosed with aggressive angiomyxoma from a single institution, between 2012 and 2020. Follow-up after surgery was ranged between 2-45 months with an average of 17.6 months. Resection was performed in all patients without any complications, and five had received GnRH analogue (Goserelin acetate) therapy after surgery. Immunohistochemistry analyses showed positivity for smooth muscle actin and desmin in all cases, while both estrogen receptor (ER) and progesterone receptor (PR) positivity were identified in 6 patients. None of the seven patients had recurrence during follow up period.
The mean treatment of aggressive angiomyxoma is surgery, and the use of GnHR analogues in cases with positive ER and PR may be effective in preventing recurrence.
Aggressive Angiomyxoma, Gonadotropin-Releasing Hormone, Soft Tissue Neoplasm.
侵袭性血管黏液瘤是一种主要发生于盆腔和会阴区域的间叶性肿瘤。我们研究的目的是揭示我们在血管黏液瘤患者中使用促性腺激素释放激素（GnRH）治疗的经验，并提供一份全面的治疗综述。
本研究为病例系列研究，纳入了2012年至2020年间在单一机构确诊为侵袭性血管黏液瘤的7名女性患者。术后随访时间为2至45个月，平均17.6个月。所有患者均接受了手术切除，且无任何并发症，其中5名患者术后接受了GnRH类似物（醋酸戈舍瑞林）治疗。免疫组化分析显示所有病例平滑肌肌动蛋白和结蛋白均呈阳性，6例患者雌激素受体（ER）和孕激素受体（PR）均呈阳性。7名患者在随访期间均未复发。
侵袭性血管黏液瘤的主要治疗方法是手术，对于ER和PR阳性的病例，使用GnHR类似物可能有效预防复发。
侵袭性血管黏液瘤；促性腺激素释放激素；软组织肿瘤
